NO20074826L - Epidermalveksfaktorreseptormutasjoner - Google Patents

Epidermalveksfaktorreseptormutasjoner

Info

Publication number
NO20074826L
NO20074826L NO20074826A NO20074826A NO20074826L NO 20074826 L NO20074826 L NO 20074826L NO 20074826 A NO20074826 A NO 20074826A NO 20074826 A NO20074826 A NO 20074826A NO 20074826 L NO20074826 L NO 20074826L
Authority
NO
Norway
Prior art keywords
mutant
egfr
raf
methods
treating tumors
Prior art date
Application number
NO20074826A
Other languages
English (en)
Norwegian (no)
Inventor
Daniel J Freeman
Todd Juan
Robert Radinsky
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO20074826L publication Critical patent/NO20074826L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
NO20074826A 2005-02-24 2007-09-21 Epidermalveksfaktorreseptormutasjoner NO20074826L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65626305P 2005-02-24 2005-02-24
PCT/US2006/006751 WO2006091899A2 (fr) 2005-02-24 2006-02-23 Mutations de recepteur de facteur de croissance epidermique

Publications (1)

Publication Number Publication Date
NO20074826L true NO20074826L (no) 2007-11-23

Family

ID=36579263

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074826A NO20074826L (no) 2005-02-24 2007-09-21 Epidermalveksfaktorreseptormutasjoner

Country Status (15)

Country Link
US (2) US7981605B2 (fr)
EP (1) EP1851243A2 (fr)
JP (2) JP2008535477A (fr)
KR (1) KR20070106029A (fr)
CN (1) CN101208354A (fr)
AU (2) AU2006216477A1 (fr)
BR (1) BRPI0607235A2 (fr)
CA (1) CA2601936C (fr)
CR (1) CR9390A (fr)
EA (1) EA013617B1 (fr)
IL (1) IL185210A0 (fr)
MX (1) MX2007009963A (fr)
NO (1) NO20074826L (fr)
WO (1) WO2006091899A2 (fr)
ZA (1) ZA200707379B (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084058A2 (fr) 2005-02-03 2006-08-10 The General Hospital Corporation Methode de traitement du cancer resistant au gefitinib
ES2586410T3 (es) 2005-02-11 2016-10-14 Memorial Sloan-Kettering Cancer Center Procedimientos y composiciones de detección de un mutante de EGFR resistente a fármacos
JP5276017B2 (ja) * 2007-01-25 2013-08-28 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｅｇｆｒ変異体仲介性疾患の治療における抗ｅｇｆｒ抗体の使用
US9340601B2 (en) 2007-03-01 2016-05-17 The Board Of Trustees Of The Leland Stanford Junior University Splice variants of the EGF receptor
NZ578943A (en) 2007-03-01 2012-09-28 Symphogen As Recombinant anti-epidermal growth factor receptor antibody compositions
JP2010521154A (ja) * 2007-03-13 2010-06-24 アムゲン インコーポレイティッド Ｋ‐ｒａｓ変異およびＢ‐ｒａｆ変異ならびに抗ＥＧＦｒ抗体療法
GB2453173A (en) * 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
TW201002346A (en) * 2008-04-11 2010-01-16 Galaxy Biotech Llc Combination of HGF inhibitor and EGF inhibitor to treat cancer
ES2958968T3 (es) 2008-06-17 2024-02-16 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
EP2313758B1 (fr) * 2008-07-17 2012-02-01 Koninklijke Philips Electronics N.V. Dispositif à nanopores et procédé pour analyse d'acide nucléique
AU2009287163B2 (en) 2008-08-29 2014-11-13 Les Laboratoires Servier Recombinant anti-Epidermal Growth Factor Receptor antibody compositions
CN101445832B (zh) * 2008-12-23 2011-09-14 广州益善生物技术有限公司 Pik3ca基因突变的检测探针、液相芯片及其检测方法
EP3722810A3 (fr) * 2009-02-11 2021-01-13 Caris MPI, Inc. Profilage moléculaire de tumeurs
WO2011031861A1 (fr) * 2009-09-09 2011-03-17 Quintiles Transnational Corp. Procédés pour la prédiction de la sensibilité d’une maladie ou d’un trouble à un inhibiteur de la tyrosine kinase de récepteurs par l’analyse de mutations dans le gène pik3ca
WO2012005383A2 (fr) * 2010-07-07 2012-01-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 Procédé de production de cellules tumorales à partir de cellules épithéliales mammaires normales
US20120164641A1 (en) * 2010-12-22 2012-06-28 Roche Molecular Systems, Inc. Methods and Compositions for Detecting Mutation in the Human Epidermal Growth Factor Receptor Gene
MX2013011706A (es) 2011-04-07 2014-04-25 Amgen Inc Proteinas novedosas de enlace a antigeno.
AU2012253525B2 (en) * 2011-05-10 2016-09-22 Brunangelo Falini Hairy cell leukemia biomarkers and methods of using same
EP2554551A1 (fr) * 2011-08-03 2013-02-06 Fundacio Institut mar d'Investigacions Médiques (IMIM) Mutations du gène du récepteur de facteur de croissance épidermique
US20140005119A1 (en) * 2012-06-28 2014-01-02 Case Western Reserve University COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF P110a MUTANT PROTEINS
KR20150136588A (ko) * 2013-01-14 2015-12-07 내셔널 타이완 유니버시티 Ｅｇｆｒ의 발현을 침묵시키기 위한 ｄｎａ자임
CN103739713B (zh) * 2013-12-10 2016-03-09 吴炯 一种新型诱导肺瘤细胞凋亡的融合蛋白及其应用
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
GB2521355A (en) * 2013-12-17 2015-06-24 Kymab Ltd Human targets I
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
WO2015092394A1 (fr) * 2013-12-17 2015-06-25 Kymab Limited Anticorps destinés à être utilisés pour traiter des états associés à des variants spécifiques de pcsk9 chez des populations de patients spécifiques
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
CN105779480B (zh) * 2016-03-24 2020-03-20 成都康景生物科技有限公司 一种携带多位点突变型egfr新抗原基因的重组腺相关病毒载体及构建方法和应用
EP3534947A1 (fr) 2016-11-03 2019-09-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
US9980967B1 (en) 2017-03-16 2018-05-29 National Chiao Tung University Method for overcoming drug resistance of EGFR mutation and cancerous stemness of human non-small cell lung carcinoma
CN108047308A (zh) * 2018-02-02 2018-05-18 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108047309A (zh) * 2018-02-07 2018-05-18 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108250268A (zh) * 2018-02-08 2018-07-06 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108218960A (zh) * 2018-03-07 2018-06-29 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108218959A (zh) * 2018-03-07 2018-06-29 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108409832A (zh) * 2018-03-07 2018-08-17 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108218961A (zh) * 2018-03-19 2018-06-29 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440649A (zh) * 2018-05-31 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108752424A (zh) * 2018-06-04 2018-11-06 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440650A (zh) * 2018-06-04 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440651A (zh) * 2018-06-08 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN109485721A (zh) * 2018-11-23 2019-03-19 杜学明 一种获得肿瘤特异性t细胞受体的方法
RU2706116C1 (ru) * 2018-12-26 2019-11-14 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ прогнозирования течения аденокарциномы легкого
WO2020145715A1 (fr) * 2019-01-11 2020-07-16 주식회사 진캐스트 Adn polymérase pour détecter des mutations tert et trousse comprenant cette derniere
WO2020145754A1 (fr) * 2019-01-11 2020-07-16 주식회사 진캐스트 Spectrométrie de masse utilisant une adn polymérase avec une spécificité de mutation génétique accrue
WO2020145711A1 (fr) * 2019-01-11 2020-07-16 주식회사 진캐스트 Adn polymérase pour la détection de mutation d'egfr et trousse comprenant celle-ci
EP3931224A4 (fr) 2019-02-26 2023-03-01 Janssen Biotech, Inc. Traitements combinés et stratification des patients avec des anticorps bispécifiques anti-egfr/c-met
WO2020230091A1 (fr) 2019-05-14 2020-11-19 Janssen Biotech, Inc. Polythérapies avec des anticorps anti-egfr/c-met bispécifiques et des inhibiteurs de tyrosine kinase egfr de troisième génération
CN113993544A (zh) * 2019-07-24 2022-01-28 神州细胞工程有限公司 用于治疗egfr高表达的癌症的多变剂量方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
AU639726B2 (en) * 1989-09-08 1993-08-05 Duke University Structural alterations of the egf receptor gene in human gliomas
EP1276771A4 (fr) * 2000-03-10 2003-06-04 Thomas Jefferson Univarsity Detection sensible du recepteur egf mutant de type sauvage par analyses specifiques d'elisa dans un echantillon biologique
WO2005027710A2 (fr) * 2002-09-11 2005-03-31 Sequenom, Inc. Procedes d'identification de sujets a risque pour le melanome et traitements correspondants
KR101347613B1 (ko) * 2004-03-31 2014-01-06 다나-파버 캔서 인스티튜트 인크. 암에 걸린 인간 환자의 표피성장인자 수용체 표적 치료의 유효 가능성 결정 방법, 키트, 핵산 프로브 및 프라이머쌍
EP3042964A1 (fr) * 2004-06-04 2016-07-13 Genentech, Inc. Mutations egfr
ZA200701234B (en) * 2004-07-22 2008-12-31 Genentech Inc HER2 antibody composition
US7442507B2 (en) * 2005-01-24 2008-10-28 New York University School Of Medicine Methods for detecting circulating mutant BRAF DNA
EP1883402A2 (fr) * 2005-04-13 2008-02-06 Astex Therapeutics Limited Derives de hydroxy benzamide et leur utilisation comme inhibiteurs de hsp90
EP1913157B2 (fr) 2005-06-28 2016-10-26 Genentech, Inc. Mutations chez egfr et kras pour predire la reponse d'un patient au traitement avec un inhibiteur d'egfr

Also Published As

Publication number Publication date
EA013617B1 (ru) 2010-06-30
US8546107B2 (en) 2013-10-01
BRPI0607235A2 (pt) 2009-08-25
EP1851243A2 (fr) 2007-11-07
IL185210A0 (en) 2008-01-06
JP2012149070A (ja) 2012-08-09
WO2006091899A3 (fr) 2007-02-22
CR9390A (es) 2008-01-02
CA2601936A1 (fr) 2006-08-31
AU2010241462A1 (en) 2010-12-16
US7981605B2 (en) 2011-07-19
KR20070106029A (ko) 2007-10-31
AU2006216477A1 (en) 2006-08-31
ZA200707379B (en) 2008-10-29
WO2006091899A2 (fr) 2006-08-31
EA200701804A1 (ru) 2008-06-30
JP2008535477A (ja) 2008-09-04
CN101208354A (zh) 2008-06-25
US20070048754A1 (en) 2007-03-01
CA2601936C (fr) 2014-06-17
MX2007009963A (es) 2007-09-26
US20120328620A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
NO20074826L (no) Epidermalveksfaktorreseptormutasjoner
NO20050775L (no) Fremgangsmater for identifisering av tumorer som responderer pa behandling med anti-ErbB2-antistoffer
NO20056236L (no) Behandling med anti-VEGF-antistoffer
SG155931A1 (en) Wnt proteins and detection and treatment of cancer
BRPI0613382A8 (pt) anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
WO2007127936A3 (fr) Procédés et compositions pour la thérapie par anticorps
MX2007001986A (es) Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
NO20074817L (no) Epidermal vekstfaktorreseptor genkopiantall
MX2019007500A (es) Antagonistas de il-6 para aumentar la albumina y/o disminuir la crp.
RU2007139912A (ru) Способ прогнозирования течения рака на основе количественного анализа клеточного рецептора витамина фолата
MX2009004141A (es) Composiciones y metodos para modular receptores de c-kit y pdgfr.
NO20063569L (no) M-CSF-spesifikt monoklonalt antistoff og anvendelse derav
NO20082386L (no) Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav
RS52932B (en) K-RAS AND B-RAF MUTATIONS AND ANTI-EGFR ANTIBODY TREATMENT
EA201000325A1 (ru) Производные 2-гетероариламинопиримидина в качестве ингибиторов киназ
WO2006036173A3 (fr) Proteines frizzled et detection et traitement du cancer
BRPI0819018A2 (pt) "métodos para determinar se um paciente possui risco aumentado de desenvolver hipertensão, para determinar se um paciente possui maior probalidade de se beneficiar do tratamento com um antagonista de vegf e kits para determinar se um paciente possui risco aumentado de desenvolver hipertensão e para determinar se um paciente possui maior probabilidade de se beneficiar do tratamento com um antagonista de vegf"
WO2006034328A3 (fr) Proteines wnt et detection et traitement du cancer
Sasaki et al. Increased Sox2 copy number in lung squamous cell carcinomas
MXPA06000659A (es) Tratamiento y diagnostico de neoplasmas usando linfopoyetina estromal timica.
Lavens et al. EGFR overexpression in squamous cell carcinoma of the penis
ATE481644T1 (de) Prognose des verlaufs einer krebserkrankung
Elmogy et al. SOX2 expression inversely correlates with histological grading, nodal metastasis and clinical staging of Oral Squamous Cell Carcinoma
Justo et al. Targeted Biological Agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application